<br>        Inclusion Criteria:<br><br>          -  Have histologically confirmed Diffuse Large B-Cell Lymphoma that is either:<br><br>          -  Refractory after at least one regimen of systemic chemotherapy and/or targeted<br>             therapy, or<br><br>          -  In first or later relapse if have received at least 2 systemic regimens since time of<br>             diagnosis, or<br><br>          -  Relapsed post-autologous or allogeneic HSCT with adequate organ function after<br>             proximity to transplantation time exclusions as specified in Exclusion Criteria 208<br>             and 209<br><br>          -  Have measureable disease<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status = 2<br><br>          -  Life expectancy of = 12 weeks in the opinion of the Investigator<br><br>          -  Biopsy proven DLBCL (biopsy proven at least at primary diagnosis of DLBCL)<br><br>        Other Inclusion Criteria May Apply<br><br>        Exclusion Criteria:<br><br>          -  Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic<br>             leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)<br><br>          -  History or presence of clinically relevant Central Nervous System pathology such as<br>             epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's<br>             disease, cerebellar disease, organic brain syndrome, or psychosis.<br><br>          -  Has a diagnosis of immunodeficiency or has received systemic steroid therapy (in<br>             excess of 10 mg daily of prednisone equivalent) or any other form of immunosuppressive<br>             therapy within 7 days prior to the first dose of protocol specified therapy.<br><br>          -  Has undergone prior allogeneic HSCT:<br><br>          -  within the last 5 years OR<br><br>          -  greater than 5 years ago but has active graft versus host disease (GvHD) requiring<br>             systemic treatment.<br><br>          -  Has received autologous HSCT within 6 weeks prior to start of treatment.<br><br>        Other Exclusion Criteria May Apply.<br>